Recent

% | $
Quotes you view appear here for quick access.

Exact Sciences Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • mstevens19600 mstevens19600 Dec 19, 2012 12:34 PM Flag

    RE: SQNM's Big Announcement This AM on FLY ON THE WALL

    Your facts are distorted. Wellpoint noted limited coverage to some patients, they also listed 2 competitors they will also cover(limited) Exas has no real competitors. ttm revenue is only 71 million, not "HUNDREDS OF MILLIONS, and they show 150 million in debt.

    A reverse 3 for 1 split, 114 million shares out, book value .66 cents per share(EXAS 1.77)....nah, EXAS is a way better buy. Nice try, G/L.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Wellpoint noted NO SUCH THING LIAR MSTEVENS. (they haven't issued a press release yet, idiot). Please tell the board WTH you're smoking.
      Coverage is limited?? What do you mean? there are easily 1M births/pregnancies that will qualify coverage in the US alone. even if they penetrate 25% of that pool = 250,000 a year. Considering they will collect ~1500 per test = 250K X 1.5K = 375M revenue per year. If you consider a conservative multiple of 6X = 2.25B market cap or PPS of ~ $20 per share. If you don't understand the math then you are in the wrong business let alone your strategy here.
      My strong buy is for SQNM not this bloated junk stock EXAS

      Sentiment: Strong Buy

      • 4 Replies to blind_stupid_luck_club
      • Try clicking the link and reading the report doperbaby.

      • Investigational and not medically necessary statement revised to stipulate testing is not covered in women not at high risk for fetal aneuploidy and for women with a current multiple gestation pregnancy.

      • Try clicking the link doper
        In a medical policy update with an effective date of Dec. 19, 2012, health insurer Wellpoint (WLP) stated that it views cell-free fetal DNA-based prenatal screening for fetal aneuploidies, including but not limited to Trisomy 13, Trisomy 18 and Trisomy 21, medically necessary for its members when certain criteria are met. Wellpoint stated there are currently several commercially available laboratory developed tests which analyze circulating cell-free DNA to identify increased representation of various chromosomes, including but not necessarily limited to the Sequenom's (SQNM) MaterniT21 Test and its MaterniT21 Plus Test, among others from Verinata Health and Aria Diagnostics

      • In a medical policy update with an effective date of Dec. 19, 2012, health insurer Wellpoint (WLP) stated that it views cell-free fetal DNA-based prenatal screening for fetal aneuploidies, including but not limited to Trisomy 13, Trisomy 18 and Trisomy 21, medically necessary for its members when certain criteria are met. Wellpoint stated there are currently several commercially available laboratory developed tests which analyze circulating cell-free DNA to identify increased representation of various chromosomes, including but not necessarily limited to the Sequenom's (SQNM) MaterniT21 Test and its MaterniT21 Plus Test, among others from Verinata Health and Aria Diagnostics

 
EXAS
18.93-0.57(-2.92%)Aug 30 4:00 PMEDT